Company intelligence / Profile preview
KinaRx
Rockville, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
KinaRx is an early-stage biotechnology company developing novel small molecule kinase inhibitors primarily targeting cancers with drug resistance, with its pipeline led by a program targeting FLT3 mutations in acute myeloid leukemia (AML). Its lead compound, HSN748, is in preclinical development, with further programs for lung and medullary thyroid cancer. The company uses a proprietary kinase inhibitor discovery platform and has received notable NIH SBIR and NCI grant funding.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeKinase inhibitor
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Purdue UniversityIndiana University School of Medicine
Beyond the preview
Go deeper on KinaRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KinaRx.